Navigation Links
Oxygen Biotherapeutics, Inc. Adds Oxycyte TBI Clinical Trial Sites in Israel
Date:3/26/2009

ajor markets including traumatic brain injury, sickle cell crisis pain, trauma, wound care, acute respiratory distress syndrome, stroke, myocardial infarction, surgery, and diabetes. More information is available at www.oxybiomed.com.

Caution Regarding Forward-Looking Statements

This news release contains certain forward-looking statements by Oxygen Biotherapeutics, Inc. that involve risks and uncertainties and reflect the company's judgment as of the date of this release. The forward-looking statements include those referring to plans for dose-escalation clinical trials in Switzerland and Israel, the expected time frame for the beginning of those trials, and hoped-for data from those trials. Actual events or results may differ from Oxygen Biotherapeutics, Inc.'s expectations. There can be no assurance that the planned dose escalation studies in Switzerland and Israel will start in the expected time frame nor can there be any assurance that they will not be delayed by regulators there, or that those studies, when conducted, will be successful or provide data acceptable to the FDA. Additional information concerning these and other risk factors affecting Oxygen Biotherapeutics, Inc.'s business can be found in the company's public periodic filings with the Securities and Exchange Commission, which are available via www.oxybiomed.com. Oxygen Biotherapeutics, Inc. disclaims any intent or obligation to update these forward-looking statements beyond the date of this release. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.


'/>"/>
SOURCE Oxygen Biotherapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Oxygen Biotherapeutics, Inc. Expands Board of Directors
2. Bion Announces Approval of New Australian Patent for Low Oxygen Organic Waste Bioconversion for Livestock Waste Environmental Treatment
3. Sangart, Inc. Completes Enrollment in Second Phase III Study of Hemospan, a Novel Oxygen Transport Agent
4. Finesse Introduces TruFluor(TM) DO, a Single-Use Optical Dissolved Oxygen Sensor and Transmitter
5. Senexis and O2H (Oxygen Healthcare) Announce Medicinal Chemistry Collaboration
6. Co-Inventor of Amgens Aranesp(R) Technology Directs Worldwide Patent Strategy for Diffusion Pharmaceuticals First-in-Class Oxygen Enhancing Therapeutics
7. CardioVascular BioTherapeutics, Inc. Funding Wound Healing Trial with R&D Partnership
8. CardioVascular BioTherapeutics, Inc. Announces Update on Timing of Form 10-K Filing
9. Northwest Biotherapeutics, Inc. Announces Appointment of Chief Financial Officer
10. Exenatide Clinical Data Analysis Shows No Increased Risk of Cardiovascular Events
11. Nereus Pharmaceuticals Initiates ADVANCE, a Randomized Phase 2 Clinical Trial of NPI-2358 in Non-Small Cell Lung Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/26/2015)... SQI Diagnostics Inc. ("SQI" or the "Company") (TSX-V: SQD; ... including the appointment of auditors, its annual and special ... "Meeting") was adjourned, as previously disclosed on March 25, ... Toronto time). The date of the ... The Meeting will reconvene at the offices of the ...
(Date:3/26/2015)...  BioNano Genomics, Inc., the leader in genome mapping, ... chief commercial officer. Salyer has more than 20 years ... life sciences. At BioNano, Salyer will oversee the commercialization ... to assemble a comprehensive view of complex genomes to ... institutions located in the United States ...
(Date:3/26/2015)... Corporation (NASDAQ: NEOG ) announced today that its ... which ended Feb. 28, increased 13% to $7,454,000, when ... in the current quarter were $0.20, compared to $0.18 ... over prior year to $24,142,000, or $0.65 per share, ... same period a year ago. Revenues for ...
(Date:3/26/2015)... Houston, Texas (PRWEB) March 26, 2015 ... assist technologies, and Transonic, a supplier of precision transit-time ... board that will greatly improve the efficiency of the ... will enable LVAD patients to experience greater mobility and ... embedded with the miniature flow board, will draw 1/6th ...
Breaking Biology Technology:SQI Diagnostics Inc. Announces Adjournment of Meeting 2BioNano Genomics Appoints Terry Salyer as Chief Commercial Officer 2BioNano Genomics Appoints Terry Salyer as Chief Commercial Officer 3Neogen reports 13% increase in net income 2Neogen reports 13% increase in net income 3Neogen reports 13% increase in net income 4Neogen reports 13% increase in net income 5Neogen reports 13% increase in net income 6Neogen reports 13% increase in net income 7Neogen reports 13% increase in net income 8LVAD patients to have greater mobility and peace of mind through Transonic and ReliantHeart’s True Flow collaboration for the HeartAssist5® 2LVAD patients to have greater mobility and peace of mind through Transonic and ReliantHeart’s True Flow collaboration for the HeartAssist5® 3
... Pharmasset, Inc.,(Nasdaq: VRUS ) announced today that its ... Conference being held from September 24 - 27,2007 in ... Chief,Executive Officer, will provide an overview of the company ... To access a simultaneous webcast of the presentation via ...
... Studies Demonstrate Activity of ... Gram-Positive Bacteria, CHICAGO, Sept. 18 Astellas ... ) announced today results with the,investigational compound telavancin ... skin structure infections,(cSSSIs) from a controlled Phase 3 ...
... /PRNewswire-FirstCall/-- Biodel Inc. (Nasdaq:,BIOD) today announced additional ... 43rd Scientific Sessions of the European Association ... Phase II meal study data was disclosed ... and pharmacodynamics of,insulin VIAject(TM), insulin lispro and ...
Cached Biology Technology:Pharmasset to Present at the UBS Global Life Sciences Conference on Monday, September 24th 2Astellas and Theravance Report Additional Telavancin Data at 47th Annual ICAAC 2Astellas and Theravance Report Additional Telavancin Data at 47th Annual ICAAC 3Astellas and Theravance Report Additional Telavancin Data at 47th Annual ICAAC 4Astellas and Theravance Report Additional Telavancin Data at 47th Annual ICAAC 5Astellas and Theravance Report Additional Telavancin Data at 47th Annual ICAAC 6Biodel Inc. Announces VIAject(TM) Phase II Meal Study Data at the 2007 European Association for the Study of Diabetes Meeting 2Biodel Inc. Announces VIAject(TM) Phase II Meal Study Data at the 2007 European Association for the Study of Diabetes Meeting 3
(Date:3/17/2015)...  MecklerMedia Corporation (OTCQX: MECK) announced its ... ever held in New York City ... 2015 at the Javits Convention Center. ... Acorn Product Development; Axis NJ; c-Link Systems; CoroWare; ... NewBotic Corporation; Neya Systems LLC; Reliabotics; RoboKind; RocketFarm ...
(Date:3/12/2015)... -- Beta Systems today announced Fast ... (IAM) solution for a fixed price and with ... IAM package, customers benefit from the 30 years, ... implementations across different industries. The new fixed-price IAM ... necessary services and consulting. It spans the implementation ...
(Date:3/10/2015)...  Continuing its 167-year history of offering the Best, ... The Eye Scanning Password Authenticator , a device that ... websites or sensitive data. Employing the same ... the device has a small camera that scans and ... converting them into an encrypted ID that cannot be ...
Breaking Biology News(10 mins):MecklerMedia's RoboUniverse New York Announces Sponsors and Exhibitors, May 11-13, 2015 2Beta Systems Fast Forward IAM Available Now: a Standardized IAM Package at a Fixed Price 2Hammacher Schlemmer Introduces The Eye Scanning Password Authenticator 2
... Spanish . ,The oil spill from ... to the ecosystems in the Bay of Biscay. A PhD ... studied the consequences of this spill for the mussels inhabiting ... of the PhD thesis is the biologist Ms Larraitz Garmendia ...
... Norway MA Current research describes a new method ... onset of symptoms. The related report by Zangani et ... NF-κB activation reveals pathology in multiple organ systems," appears ... Journal of Pathology . Autoimmune diseases such as ...
... Germ cells, the cells which give rise to a ... rate of spontaneous point mutations than adult somatic cells, which ... organs. Despite their comparatively higher mutation rates, however, adult ... cloning process called somatic cell nuclear transfer (SCNT). This ...
Cached Biology News:The Prestige oil spill caused changes in the cell structure of mussels 2Stopping autoimmunity before it strikes 2Therapeutic cloning gets a boost with new research findings 2
... Spacer Leu-CMK FLISP Assay with FAM-Labeled ... nm) • Accurately measure serine protease ... permeabilization • B-Bridge's FLISP Kits utilize ... proteases (FLISPs) to measure chymotrypsin-like activity ...
Request Info...
... tool provides the firm pressure necessary ... in tubes or plates. The multifunctional ... that firmly holds thin-wall 0.5 ml ... opening or closing. A side slot ...
... microbial system, 100 to 240 V, ... of bacterial and fungal cells. This ... module for exponential decay delivery, ShockPod ... each of 0.1 and 0.2 cm ...
Biology Products: